EU Approves Bevacizumab Plus Docetaxel for First-Line Metastatic Breast Cancer Treatment

The European Commission has broadened the indication for bevacizumab. Bevacizumab can now be combined with docetaxel for the treatment of metastatic breast cancer.

The approval is based on a phase 3 trial (BO17708) where 736 patients who did not receive previous chemotherapy for their metastatic breast cancer were randomised to bevacizumab 15 mg/kg q3w in combination with docetaxel 100 mg/m2; bevacizumab 7.5 mg/kg q3w in combination with docetaxel 100 mg/m2; or placebo in combination with docetaxel 100 mg/m2 (control arm).